Posted inNews and Updates
Atumelnant Shows Promise in Reducing CAH Symptoms
New trial data shows atumelnant reduces androgen levels by 67% in CAH patients, offering a potential breakthrough to lower glucocorticoid dependency.
Posted inNews and Updates
Selinexor-Ruxolitinib Combo Shows Promise in Myelofibrosis
A study shows the Selinexor-Ruxolitinib combination meets primary endpoints for myelofibrosis, offering a new hope for patients failing JAK inhibitors.
Posted inNews and Updates
Pirtobrutinib Cuts CLL Progression Risk by 45% in Trial
New trial data confirms pirtobrutinib slashes CLL progression risk by 45%. Explore the clinical impact of this breakthrough BTK inhibitor for oncology.
Posted inNews and Updates
Decentralized Clinical Trials Market Growth Forecast 2034
Explore the projected growth of the decentralized clinical trials market through 2034 and how digital health tech is transforming global drug development.
Posted inNews and Updates
AI-Human Synergy: Accelerating Cancer Clinical Trial Access
Discover how the synergy between AI technology and clinical expertise is revolutionizing patient matching for cancer trials and accelerating research.
Posted inNews and Updates
FDA Approves First OTC Continuous Glucose Monitor for Kids
The FDA has cleared the first OTC continuous glucose monitor for children, improving access to real-time diabetes tracking and pediatric glycemic management.
Posted inNews and Updates
Decentralized Clinical Trials Market Growth Forecast to 2034
Discover the future of medical research as the decentralized clinical trials market scales globally. Explore key trends, AI integration, and 2034 forecasts.
Posted inNews and Updates
FDA Approves First OTC Continuous Glucose Monitor for Kids
The FDA has authorized the first OTC continuous glucose monitor for children. Discover how this wearable tech is changing pediatric diabetes management.
Posted inNews and Updates
Paradigm Completes Phase 3 Trial Enrollment for Arthritis
Paradigm completes enrollment for a pivotal Phase 3 osteoarthritis trial. Discover what this milestone means for the future of knee pain treatments.
Posted inNews and Updates
FDA Clears Clinical Trial for Mabwell’s 6MW5311 Injection
Mabwell has received FDA approval for the clinical trial of its novel injection, 6MW5311. Learn about this major development in drug innovation.